MK2870-022/GOG3103 A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as First-line Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1
- Phase III
- Trial Category: Gynecologic
Contact(s)
Mary Beth Wilwerding, RN Admin@NEcancertrials.com
Location(s)
Available at Methodist Estabrook Cancer Center, Omaha, NE
Interested in More Information?
Please fill out the form below. Someone will get back to you as soon as possible.
"*" indicates required fields